603590 康辰药业
已收盘 02-09 15:00:00
资讯
新帖
简况
每周股票复盘:康辰药业(603590)回购397,400股耗资2016万元
证券之星 · 02-08 02:35
每周股票复盘:康辰药业(603590)回购397,400股耗资2016万元
康辰药业公布国际专利申请:“TACC抑制剂化合物、药物组合物及其制备方法和应用”
证券之星 · 02-07 06:13
康辰药业公布国际专利申请:“TACC抑制剂化合物、药物组合物及其制备方法和应用”
2月4日康辰药业涨5.61%,汇添富医疗积极成长一年持有混合A基金重仓该股
证券之星 · 02-04
2月4日康辰药业涨5.61%,汇添富医疗积极成长一年持有混合A基金重仓该股
康辰药业涨5.61%,太平洋二个月前给出“买入”评级
证券之星 · 02-04
康辰药业涨5.61%,太平洋二个月前给出“买入”评级
1月8日康辰药业涨5.99%,前海开源医疗健康A基金重仓该股
证券之星 · 01-08
1月8日康辰药业涨5.99%,前海开源医疗健康A基金重仓该股
康辰药业涨5.99%,太平洋二个月前给出“买入”评级
证券之星 · 01-08
康辰药业涨5.99%,太平洋二个月前给出“买入”评级
康辰药业(603590.SH)发预增,预计2025年度归母净利润1.45亿元到1.75亿元,同比增加243%到315%
智通财经 · 01-07
康辰药业(603590.SH)发预增,预计2025年度归母净利润1.45亿元到1.75亿元,同比增加243%到315%
康辰药业(603590)披露股份回购进展公告,1月5日股价上涨4.03%
证券之星 · 01-05
康辰药业(603590)披露股份回购进展公告,1月5日股价上涨4.03%
康辰药业完成董事会换届及高管聘任,牛战旗续任总裁
中金财经 · 01-05
康辰药业完成董事会换届及高管聘任,牛战旗续任总裁
每周股票复盘:康辰药业(603590)选举黄憗为职工董事
证券之星 · 01-02
每周股票复盘:康辰药业(603590)选举黄憗为职工董事
康辰药业(603590)公司公告选举职工董事,12月30日股价下跌1.14%
证券之星 · 2025-12-30
康辰药业(603590)公司公告选举职工董事,12月30日股价下跌1.14%
每周股票复盘:康辰药业(603590)KC1086获FDA批准开展临床试验
证券之星 · 2025-12-28
每周股票复盘:康辰药业(603590)KC1086获FDA批准开展临床试验
康辰药业(603590.SH):KC1086项目获得FDA批准开展临床试验
智通财经 · 2025-12-24
康辰药业(603590.SH):KC1086项目获得FDA批准开展临床试验
康辰药业(603590)披露拟取消监事会并修订公司章程,12月23日股价上涨0.17%
证券之星 · 2025-12-23
康辰药业(603590)披露拟取消监事会并修订公司章程,12月23日股价上涨0.17%
康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案
中金财经 · 2025-12-16
康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案
康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组
智通财经 · 2025-12-15
康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组
异动快报:康辰药业(603590)12月3日13点13分触及涨停板
证券之星 · 2025-12-03
异动快报:康辰药业(603590)12月3日13点13分触及涨停板
康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%
证券之星 · 2025-11-26
康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%
每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股
证券之星 · 2025-11-09
每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股
康辰药业已回购40万股 金额2016万元
财中社 · 2025-11-05
康辰药业已回购40万股 金额2016万元
加载更多
公司概况
公司名称:
北京康辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2018-08-27
主营业务:
北京康辰药业股份有限公司的主营业务是化学药品制剂制造。公司的主要产品是“苏灵”、“密盖息”。
发行价格:
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":43.12,"timestamp":1770620401000,"preClose":43.01,"halted":0,"volume":2415000,"delay":0,"changeRate":0.0026,"floatShares":158000000,"shares":159000000,"eps":0.3593,"marketStatus":"已收盘","change":0.11,"latestTime":"02-09 15:00:00","open":43.03,"high":43.28,"low":42.19,"amount":103000000,"amplitude":0.0253,"askPrice":43.12,"askSize":8,"bidPrice":43.11,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.3593,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":43.01,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":47.31,"lowLimit":38.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":159010477,"isCdr":false,"pbRate":2.14,"roa":"--","peRate":120.011133,"roe":"4.04%","epsLYR":0.27,"committee":-0.778547,"marketValue":6857000000,"turnoverRate":0.0153,"status":0,"floatMarketCap":6823000000},"requestUrl":"/m/hq/s/603590","defaultTab":"news","newsList":[{"id":"2609525043","title":"每周股票复盘:康辰药业(603590)回购397,400股耗资2016万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609525043","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609525043?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:35","pubTimestamp":1770489313,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,康辰药业报收于43.01元,较上周的40.33元上涨6.65%。本周,康辰药业2月6日盘中最高价报43.43元。本周关注点公司公告汇总:康辰药业已累计回购397,400股,支付总金额20,161,793元。康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会审议通过回购股份方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2609951232","title":"康辰药业公布国际专利申请:“TACC抑制剂化合物、药物组合物及其制备方法和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2609951232","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609951232?lang=zh_cn&edition=full","pubTime":"2026-02-07 06:13","pubTimestamp":1770416014,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示康辰药业(603590)公布了一项国际专利申请,专利名为“TACC抑制剂化合物、药物组合物及其制备方法和应用”,专利申请号为PCT/CN2025/112154,国际公布日为2026年2月5日。专利详情如下:图片来源:世界知识产权组织(WIPO)今年以来康辰药业已公布的国际专利申请1个。结合公司2025年中报财务数据,2025上半年公司在研发方面投入了2049.84万元,同比减12.01%。数据来源:企查查以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020700003229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2608356068","title":"2月4日康辰药业涨5.61%,汇添富医疗积极成长一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608356068","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608356068?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:32","pubTimestamp":1770193969,"startTime":"0","endTime":"0","summary":"证券之星消息,2月4日康辰药业涨5.61%,收盘报41.61元,换手率3.21%,成交量5.07万手,成交额2.08亿元。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗积极成长一年持有混合A。汇添富医疗积极成长一年持有混合A目前规模为17.45亿元,最新净值0.6719,较上一交易日上涨0.64%,近一年上涨36.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400027231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0239","603590"],"gpt_icon":0},{"id":"2608567273","title":"康辰药业涨5.61%,太平洋二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2608567273","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608567273?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:32","pubTimestamp":1770193954,"startTime":"0","endTime":"0","summary":"今日康辰药业(603590)涨5.61%,收盘报41.61元。2025年11月5日,太平洋研究员谭紫媚,张懿发布了对康辰药业的研报《康辰药业:血凝酶市场潜力较大,在研管线临床推进顺利》,该研报对康辰药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为36.46%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长江证券的彭英骐。康辰药业(603590)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400027212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","601099"],"gpt_icon":0},{"id":"2601356868","title":"1月8日康辰药业涨5.99%,前海开源医疗健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601356868","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601356868?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:33","pubTimestamp":1767857613,"startTime":"0","endTime":"0","summary":"证券之星消息,1月8日康辰药业涨5.99%,收盘报44.39元,换手率6.55%,成交量10.36万手,成交额4.53亿元。重仓康辰药业的前十大公募基金请见下表:该股最近90天内共有7家机构给出评级,买入评级6家,增持评级1家;过去90天内机构目标均价为70.44。根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共17家,其中持有数量最多的公募基金为前海开源基金的前海开源医疗健康A。该公募基金现任基金经理为范洁。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239","150219","159891"],"gpt_icon":0},{"id":"2601568393","title":"康辰药业涨5.99%,太平洋二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601568393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601568393?lang=zh_cn&edition=full","pubTime":"2026-01-08 15:33","pubTimestamp":1767857603,"startTime":"0","endTime":"0","summary":"今日康辰药业(603590)涨5.99%,收盘报44.39元。2025年11月5日,太平洋研究员谭紫媚,张懿发布了对康辰药业的研报《康辰药业:血凝酶市场潜力较大,在研管线临床推进顺利》,该研报对康辰药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为36.46%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为长江证券的彭英骐。康辰药业(603590)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800019144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","601099"],"gpt_icon":0},{"id":"2601650876","title":"康辰药业(603590.SH)发预增,预计2025年度归母净利润1.45亿元到1.75亿元,同比增加243%到315%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601650876","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601650876?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:24","pubTimestamp":1767777888,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)发布公告,公司预计2025年年度实现归属于母公司所有者的净利润为1.45亿元到1.75亿元,同比增加243%到315%。上年度,公司根据企业会计准则对收购原泰凌医药国际有限公司(现更名:方恒医药国际有限公司)股权所形成的商誉计提商誉减值准备导致资产减值损失增加。本报告期无计提商誉减值准备的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"康辰药业(603590.SH)发预增,预计2025年度归母净利润1.45亿元到1.75亿元,同比增加243%到315%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603590"],"gpt_icon":0},{"id":"2601000725","title":"康辰药业(603590)披露股份回购进展公告,1月5日股价上涨4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601000725","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601000725?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:59","pubTimestamp":1767607150,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘,康辰药业报收于41.35元,较前一交易日上涨4.03%,最新总市值为65.75亿元。该股当日开盘39.75元,最高41.72元,最低39.56元,成交额达1.25亿元,换手率为1.94%。公司于近日发布《关于股份回购进展公告》,披露截至2025年12月31日,公司已累计回购股份397,400股,占公司总股本的0.25%。回购期间最高成交价为51.40元/股,最低成交价为49.69元/股,已支付的总金额为20,161,793元。公告称,截至披露日,本次回购符合相关法律法规及公司回购方案的要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500027084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2601559078","title":"康辰药业完成董事会换届及高管聘任,牛战旗续任总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2601559078","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601559078?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:08","pubTimestamp":1767571698,"startTime":"0","endTime":"0","summary":"中访网数据 北京康辰药业股份有限公司于2025年12月31日召开股东大会及董事会会议,完成了董事会、监事会换届及高级管理人员聘任工作。公司聘任牛战旗为总裁,刘笑寒为财务总监,黄晓东为董事会秘书,张世娜为证券事务代表,任期与本届董事会一致。公告显示,新任总裁牛战旗持有公司262,500股限制性股票,财务总监刘笑寒为公司实际控制人之子,其他新任高管未持有公司股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31913820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2600039306","title":"每周股票复盘:康辰药业(603590)选举黄憗为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2600039306","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600039306?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:56","pubTimestamp":1767297360,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,康辰药业报收于40.0元,较上周的41.68元下跌4.03%。本周,康辰药业12月22日盘中最高价报41.85元。康辰药业当前最新总市值63.21亿元,在生物制品板块市值排名38/51,在两市A股市值排名2792/5181。本周关注点公司公告汇总:康辰药业选举黄憗为第五届董事会职工董事。其任期自股东大会审议通过之日起三年,将与股东大会选举产生的其他董事共同组成第五届董事会。本次选举符合相关法律法规及《公司章程》规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2595718050","title":"康辰药业(603590)公司公告选举职工董事,12月30日股价下跌1.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595718050","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595718050?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:34","pubTimestamp":1767105258,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘,康辰药业报收于40.0元,较前一交易日下跌1.14%,最新总市值为63.6亿元。该股当日开盘40.25元,最高40.58元,最低39.82元,成交额达9114.72万元,换手率为1.44%。近日,康辰药业发布关于选举职工董事的公告。公告称,北京康辰药业股份有限公司于2025年12月29日召开职工代表大会,选举黄憗先生为公司第五届董事会职工董事。黄憗先生现任公司产品战略发展中心总经理,持有公司股份69,000股,占总股本的0.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2594242663","title":"每周股票复盘:康辰药业(603590)KC1086获FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2594242663","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594242663?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:52","pubTimestamp":1766865129,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,康辰药业报收于40.0元,较上周的41.68元下跌4.03%。本周,康辰药业12月22日盘中最高价报41.85元。本周关注点公司公告汇总:KC1086项目获FDA批准开展临床试验。康辰药业关于KC1086项目获得FDA批准开展临床试验的公告指出,公司申报的KC1086片临床试验申请已获美国食品药品监督管理局批准,同意按拟定临床研究计划开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2593835475","title":"康辰药业(603590.SH):KC1086项目获得FDA批准开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593835475","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593835475?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:42","pubTimestamp":1766569357,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)发布公告,近日,公司获得美国食品药品监督管理局(FDA)签发的《临床研究继续进行通知书》,公司申报的KC1086片临床试验申请正式获得FDA许可。KC1086 是由公司完全自主研发的一款具有全新结构的强效、高选择性赖氨酸乙酰转移酶 6(Lysine Acetyltransferase 6, KAT6)的小分子抑制剂,拟用于晚期复发或转移性实体瘤的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康辰药业(603590.SH):KC1086项目获得FDA批准开展临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2593415217","title":"康辰药业(603590)披露拟取消监事会并修订公司章程,12月23日股价上涨0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593415217","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593415217?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:28","pubTimestamp":1766500107,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘,康辰药业报收于40.74元,较前一交易日上涨0.17%,最新总市值为64.78亿元。该股当日开盘40.67元,最高40.93元,最低40.2元,成交额达7984.05万元,换手率为1.25%。根据近日发布的《康辰药业2025年第三次临时股东大会会议资料》,公司拟取消监事会,原监事会职权由董事会审计委员会行使,并将相应修订《公司章程》及相关内部制度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300040510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2591620673","title":"康辰药业拟取消监事会并修订公司章程,将召开股东大会审议多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620673","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591620673?lang=zh_cn&edition=full","pubTime":"2025-12-16 08:22","pubTimestamp":1765844541,"startTime":"0","endTime":"0","summary":"中访网数据 北京康辰药业股份有限公司于2025年12月16日发布公告,将于2025年12月31日召开2025年第三次临时股东大会。本次会议将审议多项重要议案,核心内容包括公司治理结构的重大调整及董事会换届选举。 主要审议事项如下:第一,公司拟取消监事会,并相应修订《公司章程》。其中,关于取消监事会及修订《公司章程》、《股东会议事规则》、《董事会议事规则》的议案需以特别决议通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251216/31867657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2591164645","title":"康辰药业(603590.SH):KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌Ⅱ期临床研究完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2591164645","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591164645?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:05","pubTimestamp":1765800325,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)发布公告,近日,公司自主研发的KC1036片(简称“KC1036”),顺利完成“KC1036联合PD-1抗体和含铂化疗一线治疗晚期复发或转移性食管鳞癌临床试验(KC1036-COM-01)”首例受试者入组服药。KC1036是公司自主研发的化学药品1类创新药,公司拥有该产品的全球知识产权。KC1036通过抑制VEGFR2、AXL等多靶点实现抗肿瘤活性。KC1036具有较强的VEGFR血管靶向,抑制肿瘤细胞生长;通过抑制AXL,可以改善宿主的抗肿瘤免疫应答,从而避免肿瘤的免疫逃逸。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU1169589451.USD","603590","PD","LU1169590202.USD","BK0239"],"gpt_icon":0},{"id":"2588092119","title":"异动快报:康辰药业(603590)12月3日13点13分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2588092119","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588092119?lang=zh_cn&edition=full","pubTime":"2025-12-03 13:15","pubTimestamp":1764738929,"startTime":"0","endTime":"0","summary":"证券之星12月3日盘中消息,13点13分康辰药业(603590)触及涨停板。其所属行业生物制品目前下跌。领涨股为康辰药业。该股为医药,化学原料药,创新药概念热股,当日医药概念上涨0.29%。12月2日的资金流向数据方面,主力资金净流出414.79万元,占总成交额7.63%,游资资金净流入391.5万元,占总成交额7.2%,散户资金净流入23.29万元,占总成交额0.43%。近5日资金流向一览见下表:康辰药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300016965.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"gpt_icon":0},{"id":"2586626809","title":"康辰药业(603590)披露召开2025年第三季度业绩说明会,11月26日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586626809","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586626809?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:27","pubTimestamp":1764167242,"startTime":"0","endTime":"0","summary":"截至2025年11月26日收盘,康辰药业报收于43.83元,较前一交易日下跌1.28%,最新总市值为69.85亿元。公司近日发布公告称,北京康辰药业股份有限公司将于2025年12月04日16:00-17:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会,介绍公司2025年第三季度经营成果及财务状况。投资者可于2025年11月27日至12月3日16:00前通过上证路演中心或公司邮箱ir@konruns.cn提问,公司将在说明会上对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议内容。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600039024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2582861639","title":"每周股票复盘:康辰药业(603590)董事减持3%股份,公司回购39.74万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861639","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582861639?lang=zh_cn&edition=full","pubTime":"2025-11-09 03:46","pubTimestamp":1762631172,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘,康辰药业报收于45.8元,较上周的50.5元下跌9.31%。本周,康辰药业11月3日盘中最高价报50.76元。股本股东变化高管增减持2025年10月31日,公司董事刘建华减持公司股份53.12万股,占公司总股本的0.3333%。公司公告汇总康辰药业股东减持股份结果公告本次减持计划实施前,控股股东刘建华持有公司股份50,786,760股,占公司总股本的31.87%。本次减持后,刘建华持股数量为46,006,160股,持股比例为28.87%,实际减持情况与此前披露一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"gpt_icon":0},{"id":"2581744282","title":"康辰药业已回购40万股 金额2016万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581744282","media":"财中社","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581744282?lang=zh_cn&edition=full","pubTime":"2025-11-05 16:53","pubTimestamp":1762332780,"startTime":"0","endTime":"0","summary":"11月5日,康辰药业(603590)发布公告,截至2025年10月31日已回购40万股,占总股本的0.25%,回购资金总额为2016万元,回购价格区间为49.69元/股至51.4元/股。 2025年前三季度,康辰药业实现收入6.92亿元,归母净利润1.28亿元。(文章来源:财中社)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-05/doc-infwiwtt4314955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603590","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770638927773,"stockEarnings":[{"period":"1week","weight":0.0665},{"period":"1month","weight":0.027},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.2359},{"period":"1year","weight":0.854},{"period":"ytd","weight":0.082}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10686人(较上一季度增加7.18%)","perCapita":"14806股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15901万元","survey":" 北京康辰药业股份有限公司的主营业务是化学药品制剂制造。公司的主要产品是“苏灵”、“密盖息”。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}